Literature DB >> 10984531

Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site.

Z Shriver1, R Raman, G Venkataraman, K Drummond, J Turnbull, T Toida, R Linhardt, K Biemann, R Sasisekharan.   

Abstract

Heparin- and heparan sulfate-like glycosaminoglycans (HLGAGs) represent an important class of molecules that interact with and modulate the activity of growth factors, enzymes, and morphogens. Of the many biological functions for this class of molecules, one of its most important functions is its interaction with antithrombin III (AT-III). AT-III binding to a specific heparin pentasaccharide sequence, containing an unusual 3-O sulfate on a N-sulfated, 6-O sulfated glucosamine, increases 1,000-fold AT-III's ability to inhibit specific proteases in the coagulation cascade. In this manner, HLGAGs play an important biological and pharmacological role in the modulation of blood clotting. Recently, a sequencing methodology was developed to further structure-function relationships of this important class of molecules. This methodology combines a property-encoded nomenclature scheme to handle the large information content (properties) of HLGAGs, with matrix-assisted laser desorption ionization MS and enzymatic and chemical degradation as experimental constraints to rapidly sequence picomole quantities of HLGAG oligosaccharides. Using the above property-encoded nomenclature-matrix-assisted laser desorption ionization approach, we found that the sequence of the decasaccharide used in this study is DeltaU(2S)H(NS,6S)I(2S)H(NS, 6S)I(2S)H(NS,6S)IH(NAc,6S)GH(NS,3S,6S) (+/-DDD4-7). We confirmed our results by using integral glycan sequencing and one-dimensional proton NMR. Furthermore, we show that this approach is flexible and is able to derive sequence information on an oligosaccharide mixture. Thus, this methodology will make possible both the analysis of other unusual sequences in HLGAGs with important biological activity as well as provide the basis for the structural analysis of these pharamacologically important group of heparin/heparan sulfates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984531      PMCID: PMC27029          DOI: 10.1073/pnas.97.19.10359

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Heparinase inhibits neovascularization.

Authors:  R Sasisekharan; M A Moses; M A Nugent; C L Cooney; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

2.  Preparation and biological activity of N-sulfonated chondroitin and dermatan sulfate derivatives.

Authors:  V D Nadkarni; T Toida; C L Van Gorp; R L Schubert; J M Weiler; K P Hansen; E E Caldwell; R J Linhardt
Journal:  Carbohydr Res       Date:  1996-08-26       Impact factor: 2.104

3.  Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth.

Authors:  J McLaurin; T Franklin; X Zhang; J Deng; P E Fraser
Journal:  Eur J Biochem       Date:  1999-12

4.  Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.

Authors:  T Sasaki; H Larsson; J Kreuger; M Salmivirta; L Claesson-Welsh; U Lindahl; E Hohenester; R Timpl
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

5.  Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin.

Authors:  Z Shriver; M Sundaram; G Venkataraman; J Fareed; R Linhardt; K Biemann; R Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

6.  Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites.

Authors:  T Toida; R E Hileman; A E Smith; P I Vlahova; R J Linhardt
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

7.  Genetic evidence that heparin-like glycosaminoglycans are involved in wingless signaling.

Authors:  R C Binari; B E Staveley; W A Johnson; R Godavarti; R Sasisekharan; A S Manoukian
Journal:  Development       Date:  1997-07       Impact factor: 6.868

8.  Mass spectrometric molecular-weight determination of highly acidic compounds of biological significance via their complexes with basic polypeptides.

Authors:  P Juhasz; K Biemann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  Examination of the substrate specificity of heparin and heparan sulfate lyases.

Authors:  R J Linhardt; J E Turnbull; H M Wang; D Loganathan; J T Gallagher
Journal:  Biochemistry       Date:  1990-03-13       Impact factor: 3.162

10.  Utility of non-covalent complexes in the matrix-assisted laser desorption ionization mass spectrometry of heparin-derived oligosaccharides.

Authors:  P Juhasz; K Biemann
Journal:  Carbohydr Res       Date:  1995-04-30       Impact factor: 2.104

View more
  22 in total

1.  Heparin sequencing brings structure to the function of complex oligosaccharides.

Authors:  M A Nugent
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

2.  A computational approach for deciphering the organization of glycosaminoglycans.

Authors:  Jean L Spencer; Joel A Bernanke; Jo Ann Buczek-Thomas; Matthew A Nugent
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

3.  Scientific considerations in the review and approval of generic enoxaparin in the United States.

Authors:  Sau Lee; Andre Raw; Lawrence Yu; Robert Lionberger; Naiqi Ya; Daniela Verthelyi; Amy Rosenberg; Steve Kozlowski; Keith Webber; Janet Woodcock
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

4.  Monitoring of heparin and its low-molecular-weight analogs by silicon field effect.

Authors:  Nebojsa M Milovic; Jonathan R Behr; Michel Godin; Chih-Sheng Johnson Hou; Kristofor R Payer; Aarthi Chandrasekaran; Peter R Russo; Ram Sasisekharan; Scott R Manalis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

5.  Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin.

Authors:  Zhongping Xiao; Britney R Tappen; Mellisa Ly; Wenjing Zhao; Lauren P Canova; Huashi Guan; Robert J Linhardt
Journal:  J Med Chem       Date:  2010-12-17       Impact factor: 7.446

6.  Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator.

Authors:  Youli Hu; David González-Martínez; Soo-Hyun Kim; Pierre Marc Gilles Bouloux
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

7.  Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics: insights into protein binding specificities.

Authors:  Sophie M Thompson; David G Fernig; Edwin C Jesudason; Paul D Losty; Els M A van de Westerlo; Toin H van Kuppevelt; Jeremy E Turnbull
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 8.  Therapeutically targeting protein-glycan interactions.

Authors:  A Rek; E Krenn; A J Kungl
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

9.  Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS.

Authors:  Lingyun Li; Fuming Zhang; Joseph Zaia; Robert J Linhardt
Journal:  Anal Chem       Date:  2012-09-26       Impact factor: 6.986

10.  Solid-phase synthesis of alpha-glucosamine sulfoforms with fragmentation analysis by tandem mass spectrometry.

Authors:  Runhui Liu; Chamnongsak Chanthamontri; Hongling Han; Jesús M Hernández-Torres; Karl V Wood; Scott A McLuckey; Alexander Wei
Journal:  J Org Chem       Date:  2008-07-09       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.